In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cell And Gene Therapies Are Altering Patient Expectations, Says CGT Catapult CEO

Patients Will Expect Their Condition To Be Taken Away, Rather Than Treated

Executive Summary

The Cell and Gene Therapy Catapult was established in 2012 and exists to advance the growth of the UK’s CGT industry, supporting companies in this space throughout product development and beyond. In Vivo caught up with CEO Matthew Durdy, who took over the role from Keith Thompson in 2020, to learn what the first three years of his tenure have taught him and how he sees the future of advanced therapies progressing.

You may also be interested in...

Gene Therapy Reimbursement Remains A Barrier To Commercialization

Multiple gene therapies have been approved in the last couple of years, but market access and reimbursement for gene therapies remain challenging – a key theme of the Cell & Gene Meeting on the Mesa.

UK Needs ‘National Strategy’ To Fix Cell And Gene Industry Skill Gaps

Health policy researchers have called on the UK government to address cell and gene therapy workforce gaps at a national level, warning that training academies run by “well-funded” pharma firms risk “undermining” and fragmenting the industry as a whole.

Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise

Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts